GeneDx's second quarter revenue of $114.4M beat estimates, driven by 32% growth in exome/genome volume.

GeneDx reported second quarter 2026 revenue of $114.4 million, an 11% increase year-over-year, beating analyst expectations. The company reported a GAAP loss per share of $0.60, missing estimates, but achieved an adjusted net income of $0.4 million. Full-year 2026 revenue guidance was reaffirmed at $475 to $490 million.

Key Highlights

• Exome and genome test volume grew 32% year-over-year to 30,785 tests, surpassing the company's guidance of approximately 30,000.
• Revenue from exome and genome testing increased 17% year-over-year to $100.3 million.
• Adjusted gross margin was 70.4%, up from 69% in the first quarter of 2026 and in line with expectations.
• The company secured an additional $50 million term loan facility with Blackstone, increasing its pro forma cash position to approximately $188 million.